sciencebriefs
13:00in productionCh. 1 · A stronger effect than expected/ 13:00 · ceiling 15 min
Genetics · Medicine

RNA interference

In 1998 Andrew Fire and Craig Mello found that double-stranded RNA, not single-stranded RNA, silences genes with striking potency in roundworms, revealing RNA interference as a cellular pathway now used as both a lab tool and a medicine.

Working with the roundworm Caenorhabditis elegans, Andrew Fire and Craig Mello found in 1998 that injecting double-stranded RNA silenced a matching gene far more effectively than either of its single strands alone, a result that pointed to an unrecognised natural pathway rather than a chemical curiosity. That pathway, RNA interference, works by chopping double-stranded RNA into short fragments that guide a protein complex to destroy or block matching messenger RNA, and it shares components with a related but distinct natural pathway built around microRNAs, discovered separately in the same worm by Victor Ambros and Gary Ruvkun. Fire and Mello shared the 2006 Nobel Prize in Physiology or Medicine, and Ambros and Ruvkun shared the 2024 prize for the microRNA work.

Chapters & takeaways6
  1. 0:08
    A stronger effect than expected

    Fire and Mello found double-stranded RNA silenced genes in C. elegans far more effectively than the single-stranded RNA researchers had already been trying.

  2. 2:10
    Naming RNA interference

    The unexpectedly strong effect pointed to a genuine cellular pathway, later called RNA interference, rather than a simple chemical block.

  3. 4:20
    Dicing RNA into a guide

    The pathway works by cutting double-stranded RNA into short interfering fragments that direct a protein complex to matching messenger RNA.

  4. 6:30
    A related, separately discovered pathway

    MicroRNAs, first found in C. elegans by Victor Ambros in 1993, use overlapping machinery but arise from the cell's own hairpin-shaped RNAs rather than external double-stranded RNA.

  5. 8:40
    From worm biology to a lab tool and a medicine

    RNA interference became a standard way to switch genes off for research and the basis of several approved drugs treating rare genetic conditions.

  6. 10:50
    Why the double take is worth understanding

    Worth the time because two Nobel-winning discoveries, thirteen years apart, both trace back to small RNAs silencing genes in the same worm.

Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • the surprise at the centre of the discovery, that double-stranded RNA worked when single strands had not
  • the clarity of separating RNA interference from microRNA regulation, two related pathways easy to conflate
  • the concrete line from the 1998 worm experiment to named, approved drugs
What does not
  • it does not fully explain why double-stranded RNA is so much more potent than single strands at the biochemical level
  • the account keeps the two Nobel-winning discoveries somewhat separate rather than fully integrating how their pathways overlap
Study it if
  • readers curious how a worm experiment became an approved medicine
  • anyone who wants to understand RNAi and microRNA as related but distinct pathways
  • students of gene regulation
Skip it if
  • readers wanting only the microRNA side of the story
  • anyone after the full structural detail of Dicer and Argonaute
The written brief3 min read

A stronger effect than expected

In 1998, Andrew Fire and Craig Mello were trying to silence specific genes in the roundworm Caenorhabditis elegans, building on earlier attempts by other researchers to switch off a gene by injecting RNA that matched its sequence, either the sense strand or its antisense complement. Neither approach worked especially well or consistently. Fire and Mello instead injected double-stranded RNA, combining both the sense and antisense strands, and found that it silenced the target gene far more effectively and specifically than either strand had managed alone. The size of the effect, and the fact that it needed only very small amounts of double-stranded RNA to work, suggested they had stumbled on a genuine, previously unrecognised biological pathway rather than a simple chemical interference.

Naming RNA interference

The phenomenon, named RNA interference, was shown to work through a specific cellular machinery rather than a general chemical effect on RNA. An enzyme called Dicer cuts long double-stranded RNA into short fragments, roughly 21 to 23 nucleotides long, known as small interfering RNAs. One strand of each fragment, the guide strand, is then loaded into a multi-protein assembly called the RNA-induced silencing complex, or RISC, while the other strand is discarded. Within RISC, a protein called Argonaute uses the guide strand to find messenger RNA with a matching sequence and either cuts it directly or blocks it from being translated into protein, silencing the corresponding gene with considerable specificity.

Dicing RNA into a guide

The core finding, that double-stranded RNA triggers a dedicated silencing pathway built around Dicer, small interfering RNAs and RISC, has held up thoroughly and earned Fire and Mello the 2006 Nobel Prize in Physiology or Medicine. It also turned out that C. elegans harbours a related but distinct pathway built around microRNAs, short RNAs that a cell produces from its own genes rather than from external double-stranded RNA, first identified in the worm by Victor Ambros’s laboratory in 1993 and recognised as a broad regulatory class only around 2001. MicroRNAs use much of the same downstream machinery, including Argonaute, but arise differently and typically dial gene expression down rather than switching it off outright, work that brought Ambros and Gary Ruvkun the 2024 Nobel Prize.

What neither the original RNAi experiments nor the microRNA work fully settled at the outset was how the two pathways relate to each other in molecular detail, or how much of their machinery is shared versus separate; that has been worked out gradually since, across many organisms beyond the original worm. The 1998 experiment also could not, by itself, predict how directly the effect would translate into human therapy; going from silencing a gene in a transparent roundworm to safely and selectively silencing a disease-causing gene in a person required years of additional work on chemistry, delivery, and safety that lay well outside the scope of the original finding.

From worm biology to a lab tool and a medicine

RNA interference quickly became a standard laboratory tool, letting researchers switch a chosen gene off in a cell or organism to study what that gene normally does, at a scale that supports systematic screening across large numbers of genes at once. It also moved into medicine: several RNA interference-based drugs have since been approved to silence disease-causing genes, treating rare inherited conditions by cutting production of a harmful protein at its genetic source rather than targeting the protein after it is made. The related microRNA pathway has separately become a focus of disease research, since abnormal microRNA activity has been linked to conditions including certain leukaemias and other cancers.

Why the double take is worth understanding

This pairing is worth understanding together because it shows how the same organism and the same broad category of molecule, short RNAs that silence genes, produced two separate Nobel-winning discoveries thirteen years apart, each with its own trigger, its own history, and its own eventual application. Untangling RNA interference from microRNA regulation also rewards a careful reader, since casual explanation often blurs the two together despite their different origins inside the cell. An hour spent keeping the worm experiment, the pathway it revealed, and the related but distinct microRNA story straight pays off in a much clearer picture of modern gene regulation.

Same field · Genetics4 of 60
13:00
Recombinant DNAIn 1973 Stanley Cohen and Herbert Boyer showed that a gene cut from one organism with restriction enzymes could be inserted into a bacterial plasmid and expressed by the bacterium as its own, creating the first recombinant DNA. The technique became the foundation of the biotechnology industry, used by 1978 to produce synthetic human insulin, commercialised by Boyer's company Genentech and later licensed to Eli Lilly as the first approved recombinant drug. Before any product reached patients, scientists organised the 1975 Asilomar Conference and imposed a voluntary moratorium on the riskiest experiments, an early instance of a field regulating itself ahead of external pressure.
13:00
Prime editingIn October 2019, David Liu's lab at the Broad Institute, with Andrew Anzalone and Luke Koblan as lead authors, disclosed prime editing, a genome editing method that fuses a modified Cas9 that cuts only one strand of DNA to a reverse transcriptase enzyme, guided by an extended guide RNA that both finds the target and carries the template for the replacement sequence. Rather than relying on a double-strand break and the cell's own, error-prone repair pathways, as standard CRISPR-Cas9 does, prime editing writes the new sequence directly using the nicked strand as a starting point, then lets the cell's mismatch repair machinery finish installing it. That approach can perform all twelve possible single-letter DNA changes, insertions up to 44 base pairs, and deletions up to 80 base pairs, a wider range than the earlier base editors from the same lab could manage. Successive engineered versions improved editing efficiency several-fold over the original design, and by 2024 a prime editor-based therapy called PM359 had entered clinical trials, with the company reporting in 2025 that two patients treated for chronic granulomatous disease had been effectively cured.
13:00
Zinc fingerStudying how the frog Xenopus laevis makes a transcription factor called TFIIIA, Aaron Klug's laboratory at the MRC Laboratory of Molecular Biology found that the protein needed zinc ions to work, and that its sequence repeated the same short pattern of cysteines and histidines nine times over. Modelling that repeat led Klug and colleagues to the zinc finger: a compact, zinc-stabilised loop that lets a protein grip a short stretch of DNA, with several fingers strung together to read a longer sequence. The motif turned out to be one of the most common DNA-binding shapes in the genome and later became a building block for engineered gene-editing and gene-control tools.
9:37
Induced pluripotent stem cellYamanakaiPSCs are somatic cells reprogrammed to pluripotency using four transcription factors. Demonstrated in 2006 in mouse fibroblasts via retroviral delivery and Fbx15 selection. Established direct reprogramming as possible—but only to the level of Fbx15 reactivation, not full pluripotency validation.
Up next in Science

Microscope

· 13:00

Antonie van Leeuwenhoek, a self-taught draper who ground his own lenses to magnify up to roughly 300 times, reported in 1676 seeing living organisms too small for anyone to have observed before, a claim the Royal Society doubted until it sent people to Delft to check.

13:00